Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects

Amedeo F Capetti, Giuseppe V De Socio, Maria V Cossu, Gaetana Sterrantino, Giovanni Cenderello, Annamaria Cattelan, Gian M Baldin, Alessandro Soria, Niccolò Riccardi, Fosca P Niero, Benedetto M Celesia, Giorgio Barbarini, Stefano Rusconi, Giuliano Rizzardini

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance.

OBJECTIVE: Aim of the present study is to assess the long term (96-week) safety and efficacy of DTG + bDRV in a of multidrug-experienced HIV-1 infected patients, simplifying or building rescue regimens.

METHODS: All HIV-1-infected subjects from eleven Italian centers switched to DTG + bDRV between March 2014 and September 2015 were included and followed for minimum 96 weeks.

RESULTS: The cohort comprises 130 subjects, switched from 42 different, complex or at least twice-daily regimens, mainly for simplification (44.6%), viral failure (30.0%) or toxicity (16.6%). At baseline 118 had documented resistance to 1-5 antiretroviral classes and 12 lacked genotypic results either for historical reasons or for problems with primer annealing; 52 (40%) had uncontrolled viral replication, three above 500.000 copies/mL. At week 96 two showed ≥50 HIV-1 RNA copies/mL, 23 had 1-49 copies/mL and 101 had no virus detected. The proportion of subjects presenting abnormal values at baseline significantly decreased for serum glucose, creatinine, AST, total cholesterol and triglycerides.

CONCLUSIONS: These long-term data confirm the reliability of the two-drug regimen consisting of bDRV plus DTG in salvage settings in HIV-1 infection.

Original languageEnglish
Pages (from-to)242-248
Number of pages7
JournalHIV Clinical Trials
Volume19
Issue number6
DOIs
Publication statusPublished - Dec 2018

    Fingerprint

Keywords

  • Adult
  • Aged
  • Cohort Studies
  • Darunavir/therapeutic use
  • Female
  • HIV Infections/drug therapy
  • HIV Integrase Inhibitors/therapeutic use
  • HIV Protease Inhibitors/therapeutic use
  • HIV-1/drug effects
  • Heterocyclic Compounds, 3-Ring/therapeutic use
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Reproducibility of Results
  • Salvage Therapy

Cite this

Capetti, A. F., De Socio, G. V., Cossu, M. V., Sterrantino, G., Cenderello, G., Cattelan, A., Baldin, G. M., Soria, A., Riccardi, N., Niero, F. P., Celesia, B. M., Barbarini, G., Rusconi, S., & Rizzardini, G. (2018). Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clinical Trials, 19(6), 242-248. https://doi.org/10.1080/15284336.2018.1550290